L'intérêt à découvert pour Baxter Intl donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Baxter Intl. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Baxter Intl (NYSE:BAX) Stock, Rapport sur les intérêts à découvert

Baxter Intl

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.

Baxter International

Baxter International Inc

BABB

Stifel analyst Rick Wise maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Buy and lowers the price target from $46 to $38.

News

Price Target

Analyst Ratings

Stifel Maintains Buy on Baxter Intl, Lowers Price Target to $38

Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">Wall Street estimate of 78 cents</a>.
This was driven by top-line strength in Medical Products &amp; Therapies and Kidney Care, continued improvements in the integrated supply chain, and disciplined operating expense management.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41403928/us-hospitals-face-critical-iv-fluid-shortage-after-baxter-facility-shuts-down-due-to-hurricane-hel" rel="noreferrer noopener">US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene</a>
The Deerfield, Illinois-based company reported sales of $3.85 billion, in line with consensus.
Baxter&#8217;s worldwide sales include continuing sales of $2.69 billion and discontinued operations (kidney care) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41840934/baxter-reports-third-quarter-2024-results" rel="noreferrer noopener">sales of $1.15 billion</a>.
Excluding Q3 2023 BioPharma Solutions (BPS) sales and including sales of Kidney Care in both periods, worldwide Baxter sales grew 4% on both a reported and constant currency basis, in line with the company&#8217;s prior guidance.
Adjusted EPS from continuing operations was 49 cents, up 14% year-over-year.
Revenue from Medical Products &amp; Therapies increased 7% to $1.34 billion, Healthcare Systems &amp; Technologies sales increased 1% to $752 million, and Pharmaceuticals sales were up 1% to $588 million.
Last week, Baxter said it has restarted North Cove&#8217;s highest-throughput IV solutions manufacturing line.
At its peak operation (before Hurricane Helene), this line represented approximately 25% of the site&#8217;s total production and approximately 50% of the site&#8217;s production of one-liter IV solutions, the most commonly used size by hospitals and clinics.
Baxter&#8217;s current expectation is that new product from North Cove could begin shipping to distributors and customers by the end of November, ahead of its original expectations.
Guidance: &#8220;While the hurricane&#8217;s aftermath is expected to have an impact on our near-term financial outlook, we remain confident in Baxter&#8217;s outlook and growth trajectory following completion of the pending Kidney Care sale,&#8221; said José (Joe) Almeida, chair, president &amp; CEO.
Baxter expects fourth-quarter adjusted EPS of 77 cents to 81 cents, with 50 cents to 53 cents expected from continuing operations.
For the fourth quarter, the company forecasts sales from continuing operations to decline in low-single digits on a reported and constant currency basis.
For fiscal year 2024, Baxter sees adjusted EPS of $2.90-$2.94 compared to a consensus of $2.95 and <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40191263/baxter-lifts-annual-outlook-after-strong-q2-beat-medical-devices-sales" rel="noreferrer noopener">prior guidance of $2.93-$3.01</a>, including $1.81-$1.84 from continuing operations.
The company <a target="_blank" href="https://s22.q4cdn.com/911189824/files/doc_financials/2024/q3/Baxter_Reports_Third-Quarter_2024_Results_Presentation.pdf" rel="noreferrer noopener">expects</a> sales (from continuing operations) growth of around 2%.
Baxter anticipates a full-year 2025 adjusted operating margin of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100 basis point negative impact due to stranded costs. The company expects to offset these stranded costs in 2027.
Price Action: BAX stock is down 1.22% at $35.60 during the premarket session at last check Friday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41843534/astrazeneca-amgens-asthma-drug-aces-late-stage-study-in-patients-with-chronic-rhinosinusitis" target="_blank" rel="noreferrer noopener">AstraZeneca/Amgen&#8217;s Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

General

Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook

WIIM

Baxter International shares are trading lower after the company issued FY24 adjusted EPS guidance slightly below analyst expectations.

Baxter International Sees FY24 Adj. EPS $2.90-$2.94 Vs $2.95 Est.

Baxter International Sees Q4 Adj. EPS $0.77-$0.81

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.78 by 2.56 percent. The company reported quarterly sales of $3.850 billion which beat the analyst consensus estimate of $3.847 billion by 0.08 percent. This is a 3.83 percent increase over sales of $3.708 billion the same period last year.

Earnings Beats

Baxter Intl Q3 2024 Adj. EPS $0.80 Beats $0.78 Estimate, Sales $3.850B Beat $3.847B Estimate

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Baxter Intl to report an earnings per share (EPS) of $0.78.
Baxter Intl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 0.89% drop in the share price on the following day.
Here's a look at Baxter Intl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.66</td>
<td>0.61</td>
<td>0.86</td>
<td>0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.68</td>
<td>0.65</td>
<td>0.88</td>
<td>0.82</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730991682_0.png" alt="eps graph" />
<h3>Performance of Baxter Intl Shares</h3>
Shares of Baxter Intl were trading at $36.11 as of November 06. Over the last 52-week period, shares are up 8.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Baxter Intl</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Baxter Intl.
Baxter Intl has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $40.0, the consensus suggests a potential 10.77% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Hologic, Insulet and Zimmer Biomet Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Hologic is favoring an Neutral trajectory, with an average 1-year price target of $88.67, suggesting a potential 145.56% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Insulet, with an average 1-year price target of $260.22, implying a potential 620.63% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Zimmer Biomet Holdings, with an average 1-year price target of $119.27, indicating a potential 230.3% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Hologic, Insulet and Zimmer Biomet Holdings, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxter Intl</td>
<td>Neutral</td>
<td>2.83%</td>
<td>$1.43B</td>
<td>-3.97%</td>
</tr>
<tr>
<td>Hologic</td>
<td>Neutral</td>
<td>-2.32%</td>
<td>$560.30M</td>
<td>3.54%</td>
</tr>
<tr>
<td>Insulet</td>
<td>Buy</td>
<td>23.20%</td>
<td>$330.90M</td>
<td>21.08%</td>
</tr>
<tr>
<td>Zimmer Biomet Holdings</td>
<td>Neutral</td>
<td>4.03%</td>
<td>$1.29B</td>
<td>1.98%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Baxter Intl ranks in the middle among peers for consensus rating. It ranks at the bottom for revenue growth. It ranks at the top for gross profit. It ranks at the bottom for return on equity.
<h3>About Baxter Intl</h3>
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
<h3>Financial Insights: Baxter Intl</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Baxter Intl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.83% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.24%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Baxter Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -3.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Baxter Intl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.75, Baxter Intl faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/BAX/earnings">To track all earnings releases for Baxter Intl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Baxter Intl's Earnings Preview

<a href="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates#:~:text=Based%20on%201">https://www.baxter.com/baxter-newsroom/hurricane-helene-updates#:~:text=Based%20on%201</a>
&nbsp;
Baxter's North Cove manufacturing site was significantly impacted by the rain and storm surge from Hurricane Helene, which was unprecedented in Western North Carolina and resulted in water flooding the facility.&nbsp;
Supporting our employees in the impacted communities, bringing the North Cove facility back online and helping to ensure ongoing supply to patients are our top priorities. &nbsp;
"Recovery progress at our North Cove site continues to be very encouraging. In a matter of weeks, our team has advanced from the depths of Hurricane Helene's impact to restarting our highest-throughput manufacturing line. This is a pivotal milestone, but more hard work remains as we work to return the plant to full production. I want to recognize the dedication of our North Cove team as well as the countless Baxter employees globally who have committed themselves to helping contribute to supply continuity amid this unprecedented challenge. I also offer Baxter's gratitude for the steadfast support of ASPR, FDA, the State of North Carolina and HHS. And we are deeply appreciative of our customers' patience and partnership as progress continues."&nbsp;
-- José (Joe) E. Almeida, chair, president and chief executive officer&nbsp;
&nbsp;
Below are the latest updates in each area:&nbsp;
Employees and Community: We salute our North Cove team, who are fueling our recovery while continuing to navigate the storm's personal toll.&nbsp;
<ul>
<li>All 2,500+ North Cove employees have been accounted for following Hurricane Helene. Employees are returning to work at pre-hurricane staffing levels, working alongside remediation contractors that have been engaged on a temporary basis for site recovery. &nbsp;</li>
<li>Our local colleagues are simultaneously continuing to navigate the storm's devastating personal and community impact. Baxter continues to offer critical employee assistance through a range of initiatives: &nbsp;
<ul>
<li>NEW: The Baxter International Foundation has donated ~$4 million to support employees and communities impacted by Hurricane Helene, including $1.5 million in grants to three humanitarian partners and nearly $2.5 million in funding to employees through Baxter's Employee Disaster Relief Fund.&nbsp;</li>
<li>An employee support center provides basic supplies, such as food, water, and toiletries, as well as access to portable generators, showers, laundry machines, credit union services, and laptop workstations with internet access. &nbsp;</li>
<li>Colleagues at multiple Baxter sites across the U.S. have initiated clothing drives to collect cold weather gear and other items for delivery to the North Cove team. &nbsp;</li>
</ul>
</li>
</ul>
Facilities and Infrastructure: As previously shared, and in coordination with FDA, our goal remains to begin resuming North Cove production in phases by the end of this year. &nbsp;
<ul>
<li>NEW: We are pleased to announce that Baxter has restarted the highest-throughput IV solutions manufacturing line. At its peak operation (prior to Hurricane Helene), this line represented approximately 25% of the site's total production and approximately 50% of the site's production of one-liter IV solutions, the most commonly used size by hospitals and clinics. &nbsp;
<ul>
<li>Initial batches will be manufactured concurrently with ongoing quality activities and would only be released in accordance with applicable regulatory requirements to ensure the quality and safety of the products. &nbsp;</li>
<li>It is important to note that the earliest that new North Cove product could start to ship is late November. This is ahead of our original expectations and a testament to the urgency, diligence and resiliency of the North Cove and broader Baxter teams as we've worked to accelerate recovery, with the coordination of FDA, ASPR and HHS.&nbsp;</li>
<li>Assessment and repair of equipment with phased testing continues to progress across all other production lines, which will, in coordination with FDA, support resumption of operations in phases.&nbsp;</li>
<li>We do not yet have a timeline for when we expect North Cove production to be fully restored to pre-hurricane levels.&nbsp;</li>
</ul>
</li>
<li>NEW: Our first temporary bridge has already transported more than 885 truckloads of finished product off site and to customers. &nbsp;
<ul>
<li>We continue to make progress on the second temporary bridge being installed at the site, thanks to the support of ASPR, North Carolina Department of Transportation and our local team. This bridge, currently estimated to be completed in early November, will enable additional truck and equipment traffic to enter and leave the site.&nbsp;</li>
</ul>
</li>
</ul>
Supply Continuity: We are grateful for the ongoing partnership and efforts of our customers as we navigate this complex and challenging situation to prioritize patient care.&nbsp;
<ul>
<li>Global Manufacturing Network: To date, we have activated nine plants across our global network to help increase available inventory, which is contemplated in current allocation levels. &nbsp;</li>
<li>U.S. Expiry Extensions for IV and Irrigation Products: Baxter has received FDA authorization to extend the use dates of 50+ IV and irrigation codes to provide up to an additional 12 months of expiry. Products now have a 24-month expiry period from the date of manufacture. This extension only applies to products manufactured prior to the end of September 2024. Details have been communicated directly to customers.&nbsp;</li>
<li>U.S. Distribution for Products Authorized for Temporary Importation: Baxter has communicated to customers its distribution plans for products authorized for temporary importation. We are carefully managing the availability of both previously finished goods coming out of North Cove and the import of product to the U.S., providing specific resources and training to those customers receiving product imported to the U.S.&nbsp;</li>
<li>Conservation: Conservation efforts for IV and PD solutions across the healthcare system remain essential to supplement allocation levels and help preserve supply, and we are grateful for our customers' efforts in this area. Our Medical Affairs team is offering support and resources for product management and conservation strategies. <a href="https://meded.baxter.com/hurricane-helene-resources">Visit our clinical webpage</a> for more information. &nbsp;</li>
<li>IV Solutions Allocations: &nbsp;
<ul>
<li>In the U.S., allocation levels for both direct customers and distributors remain as previously communicated by Baxter on Oct. 9th. &nbsp;</li>
<li>Based on 1) the current status of our North Cove remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) temporary importation on certain products, our goal remains to return to 90% to 100% allocation of certain IV solution product codes for U.S. customers by the end of 2024.&nbsp;</li>
</ul>
</li>
<li>NEW: U.S. PD Patient Starts: We have begun to expand our support for new peritoneal dialysis (PD) patients on a limited basis, beyond the highly restricted medical exceptions to date, to help providers address urgent medical needs. The volume of new patients should continue to increase in the coming weeks, with the goal of returning to pre-Hurricane Helene levels for new patient starts by the end of the year.&nbsp;</li>
<li>PD Solutions Allocations and Ongoing Patient Support:&nbsp;
<ul>
<li>We are closely partnering with the kidney community, including physicians, nurses and care teams, to enhance our support for patients. This includes working to improve the ordering and delivery process to help reduce wait times and increase the accuracy of our target delivery dates and times. We are grateful to have excellent provider partners, who have been agile and proactive in helping us meet patient needs while conserving supply. Because PD patients have individualized prescriptions, this has allowed for some additional flexibility in our ongoing ability to support them within the allocation protocols already put in place. &nbsp;</li>
<li>While the allocations for PD solutions in the U.S. currently remain as communicated with patients and clinicians, thanks to FDA's recent temporary importation authorizations, we are temporarily importing additional product into the U.S. to help support supply. We will be providing training and education materials in the first part of November so that patients and care teams can prepare to use these imported PD solutions. Our global footprint and quality standards have allowed us to rapidly respond and shift supply accordingly, to help address the needs of existing and new patients in the U.S.&nbsp;</li>
</ul>
</li>
</ul>

Biotech

Baxter Gives Hurricane Helene Updates; Baxter Has Restarted The Highest-throughput IV Solutions Manufacturing Line

<a href="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates#:~:text=Based%20on%201" title="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates#:~:text=Based%20on%201">https://www.baxter.com/baxter-newsroom/hurricane-helene-updates#:~:text=Based%20on%201</a>

Baxter Says Anticipates Restarting Highest-Throughput IV Solutions Manufacturing Line Within Next Week; FDA Authorized Temporary Importation For Variety Of Product Codes From 2 Additional Baxter Manufacturing Facilities, In Thailand & Singapore; Goal Remains To Return To 90% To 100% Allocation Of Some IV Solution Product Codes For U.S. Customers By 2024 End

The United States is facing a significant shortage of intravenous (IV) fluids, including saline and dextrose solutions, exacerbated by damage to Baxter International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) plants in North Carolina <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41340376/baxters-north-carolina-plant-recovery-underway-after-hurricane-flooding-starts-product-imports" rel="noreferrer noopener">due to Hurricane Helene</a>.
These essential fluids, already in limited supply before the hurricane, are critical for various medical treatments, such as hydration, wound cleaning, and dialysis.
The closure of Baxter&#8217;s plant, which produces about 60% of the country&#8217;s IV fluids, has intensified the scarcity, leaving hospitals struggling to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41257734/baxters-north-carolina-facility-manufactures-60-of-iv-fluids-and-peritoneal-dialysis-solutions-s" rel="noreferrer noopener">maintain adequate supplies</a>.
An NBC <a href="https://www.nbcnews.com/health/health-news/long-helene-iv-fluid-shortages-plagued-hospitals-rcna175563">report </a>noted that years before the hurricane, the U.S. was already experiencing shortages of IV fluids, according to the FDA.
Saline solution has been in short supply since 2018, sterile water since 2021, and dextrose solution since early 2022.
The hurricane worsened the situation, adding lactated Ringer&#8217;s solution and peritoneal dialysis fluids to the list of shortages.
This shortage is a critical issue as hospitals depend on these fluids for life-saving treatments, and they are challenging to produce due to high regulatory standards and the delicate sterilization process involved.
Erin Fox, senior pharmacy director at the University of Utah Health, told NBC that the low profitability of manufacturing these fluids has deterred companies from entering the market.
IV fluids require significant space and resources to produce and store, and their relatively low cost creates little financial incentive for drugmakers.
Speaking to NBC, Michael Ganio, senior director of pharmacy practice at the American Society of Health-System Pharmacists, added that controlling endotoxins, harmful bacteria resistant to sterilization, further complicates the production process.
In response to the crisis, the federal government has invoked the Defense Production Act, enabling Baxter to secure priority access to materials necessary to rebuild its North Carolina facility.
The FDA has also allowed Baxter to temporarily import IV fluids from plants in Canada, China, Ireland, and the U.K. Despite these efforts, Baxter expects to meet only 90% of its customers&#8217; needs by the end of the year.
The shortage affects hospitals, with many postponing elective surgeries due to insufficient IV fluid supplies.
Citing some analysts, Reuters highlighted that the impact on medical device manufacturers, such as Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) and Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), will be minimal if the shortage is resolved by early next year.
However, the situation remains concerning for hospital operators like HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), as delays in surgeries could affect their revenues.
Baxter <a target="_blank" href="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates" rel="noreferrer noopener">announced</a> that the first FDA-authorized product shipments for temporary importation are set to arrive in the U.S. this weekend.
In collaboration with the ASPR, the company estimates that by year-end, about 200 Boeing 747 cargo planes—equivalent to nearly 18,000 tons of product—will be delivered from Europe and Asia.
Providers could begin receiving these shipments in the coming weeks.
Price Action: Shares of BAX were up 0.02% at $36.66 at the time of publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41401926/aura-biosciences-bladder-cancer-candidate-demonstrates-tumor-shrinkage-in-patients-with-high-grad" target="_blank" rel="noreferrer noopener">Aura Biosciences&#8217; Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease</a>.</li>
</ul>
Photo: SeventyFour/Shutterstock.com

Large Cap

US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene

On Monday, Baxter International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) said over 1,000 employees came back to work last week after the North Cove facility was shut down following significant damage <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41257734/baxters-north-carolina-facility-manufactures-60-of-iv-fluids-and-peritoneal-dialysis-solutions-s" rel="noreferrer noopener">caused by Hurricane Helene</a>.
Additionally, more than 1,000 remediation contractors are on site to assist with cleanup and recovery.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40342215/baxter-seals-3-8b-deal-with-carlyle-for-its-kidney-care-segment" rel="noreferrer noopener">Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment</a>
This week, the company expects 3,000 people to contribute to recovery efforts, nearly two-thirds of whom are Baxter employees.
Baxter noted that the primary focus is deep cleaning the facility, including floors and equipment, and assessing the condition of all equipment and production lines.
The first temporary bridge has already allowed the transportation of over 350 truckloads of finished products, enabling customer shipments to resume.
The dialysis device maker began shipments of intravenous products to the United States from two international facilities last week.
Last week, the FDA <a target="_blank" href="https://www.fda.gov/drugs/updates-2024-hurricane-season/hurricane-helene-baxters-manufacturing-recovery-north-carolina" rel="noreferrer noopener">said</a> it is working to temporarily import some products in shortage. The FDA allowed product imports from five facilities in Canada, China, Ireland, and the U.K., and it was working to secure authorization for more sites.
As shared earlier, Baxter <a target="_blank" href="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates" rel="noreferrer noopener">aims</a> to restart North Cove production in phases by the end of this year but did not share the timeline for fully restoring production to pre-hurricane levels.
North Cove is Baxter&#8217;s largest facility and is responsible for manufacturing approximately 60% of IV fluids and peritoneal dialysis solutions available to healthcare providers in the U.S.
Shipments to the U.S. from two Baxter sites that could already export products started last week, and more shipments are coming.
Price Action: BAX stock is up 0.41% at $37.06 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41338643/sofi-and-nova-credit-boost-partnership-new-cash-flow-analytics-to-transform-loan-approvals" target="_blank" rel="noreferrer noopener">SoFi And Nova Credit Boost Partnership, New Cash Flow Analytics To Transform Loan Approvals</a>.</li>
</ul>

Baxter's North Carolina Plant Recovery Underway After Hurricane Flooding, Starts Product Imports

U.S. Senator Amy Klobuchar (D-MN) is calling on U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra to utilize all available resources to tackle the national shortage of <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41105907/hurricane-helene-shutters-baxter-internationals-key-manufacturing-hub-in-north-caro" rel="noreferrer noopener">intravenous (IV) solutions</a>.
This crisis <a target="_blank" href="https://www.klobuchar.senate.gov/public/index.cfm/news-releases?ID=9E1FF11A-FBC0-46D5-B7FF-67A92458EA14" rel="noreferrer noopener">follows</a> the shutdown of Baxter International&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) largest IV solutions manufacturing facility due to flooding from Hurricane Helene.
With Hurricane Milton looming, Senator Klobuchar warns that another facility in Daytona Beach, Florida, may also be at risk, worsening the current situation.
The Baxter facility is responsible for manufacturing approximately 60% of IV fluids and peritoneal dialysis solutions available to health care providers in the U.S.
Senator Klobuchar expressed deep concern over the implications of this shortage on patient care.
&#8220;Flooding from Hurricane Helene compromised the safe operations, inventory, raw materials and roadway access at Baxter International&#8217;s intravenous (IV) solution plant in Marion, North Carolina,&#8221;&nbsp;wrote Senator Klobuchar.&nbsp;
&#8220;As a result of Hurricane Helene, hospitals, dialysis centers, and other health care providers around the country—including many in Minnesota—are already being forced to ration these basic, but life-saving supplies.&#8221;&nbsp;
To mitigate the impact of this critical shortage, Klobuchar urged the HHS to act swiftly, coordinating with the Federal Trade Commission and the Department of Justice to prevent the distribution of counterfeit IV solutions.
She called for measures to safeguard against price gouging and other illegal practices by companies marketing FDA-approved IV solutions.
Klobuchar stressed that no single entity should dominate the supply of such vital medical resources, as this poses a significant risk to national health and safety.
The senator&#8217;s efforts to combat drug shortages are not new.
The German healthcare group Fresenius SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FSNUF#OTC">FSNUF</a>) announced that its generic hospital drugs division, Fresenius Kabi, has recently commenced the production of intravenous (IV) solutions at a new facility in Wilson, North Carolina.
Additionally, Reuters highlighted the company is exploring options to expedite the launch of additional production lines at this unaffected site.
Fresenius said increasing U.S. production at the Wilson facility will take several months, but it won&#8217;t be sufficient to offset a prolonged shutdown at Baxter.
Price Action: BAX stock is up 2% at $37.87 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41254817/honeywell-expands-qualcomm-partnership-ai-and-connectivity-to-supercharge-energy-industry-operat" target="_blank" rel="noreferrer noopener">Honeywell Expands Qualcomm Partnership: AI And Connectivity To Supercharge Energy Industry Operations</a>.</li>
</ul>

Equities

Media

FSNUF

Baxter's North Carolina Facility Manufactures ~60% Of IV Fluids And Peritoneal Dialysis Solutions, Senator Demands Immediate Action To Protect Patient Care Amid Shortage

Baxter Increasing Current U.S. Allocation Levels Of Highest Demand IV Fluids For Direct Customers From 40% To 60%; Increasing Current U.S. Allocation Levels Of Highest Demand IV Fluids For Distributors From 10% To 60%, Effective October 9, 2024

HHS Says FDA Working With Baxter To Identify Potential Products In System, Alternative Manufacturing Sites, Including For Potential Temporary Imports; FDA Will Continue To Work With Baxter As They Bring Their Plant Back Online And With Other Suppliers To Increase Supply

HHS Says Impacts Of Hurricane Helene Have Led To Temporary Supply Disruption At Baxter Facility In Marion, North Carolina; Coordinating USG-Wide Response To Address Supply Chain Disruptions; Hurricane-Related Supply Disruption At Baxter Facility Will Likely Lead To Further Constraints For Iv Fluids; Baxter Reported They Resumed Shipments To Hospitals, Dialysis Providers, Patients After Temporary Hold Last Week Due To Hurricane Helene

AMN Healthcare Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amn#NYSE">AMN</a>) launched an innovative technology suite, WorkWise, last Wednesday. The suite is expected to unify the company&#39;s technologies into one single technology offering.
Per AMN Healthcare, WorkWise has been designed to streamline workforce processes by combining the capabilities of quantifying staffing demand with predictive scheduling, automated workforce management and enhanced clinician engagement using AI technology. The technology suite will likely empower healthcare systems to efficiently source the appropriate talent, while effectively managing costs.
The latest launch is expected to significantly boost AMN Healthcare&#39;s Technology and Workforce Solutions business and solidify its foothold in the healthcare space.
<h2>Likely Trend of AMN Stock Following the News</h2>
Following the announcement on Oct. 2, shares of the company moved nearly 2.8% south to $38.64 at yesterday&#39;s close.
Historically, the company has gained a high level of synergies from its product launches. Although the latest launch is likely to be beneficial for AMN&#39;s top-line growth going forward, the stock declined overall since the announcement despite a slight gain yesterday.
AMN Healthcare currently has a market capitalization of $1.47 billion. It has an earnings yield of 8.3%, higher than the industry&#39;s 3.6%. In the last reported quarter, AMN delivered an earnings surprise of 30.7%.
<h2>Significance of the Launch of AMN Healthcare&#39;s WorkWise</h2>
Per AMN Healthcare, WorkWise is completely integrated with healthcare organizations&#39; internal systems. This is expected to enable hospitals to optimize personnel for any type of job (permanent, per diem, contract), sourcing from internal and external talent, to reduce costs and predict staffing needs with greater precision. The solution will likely leverage automation and data analysis to provide insights and build engaged talent networks for effective workforce management and increased speed-to-fill for staffing needs.
AMN Healthcare&#39;s management believes that WorkWise will be an integrated solution with multiple capabilities that can work together to address complex workforce challenges in the healthcare industry. It is expected to provide a full end-to-end solution for hospitals and healthcare systems, which is built to adapt and evolve with their needs.
<h2>Industry Prospects in Favor of AMN</h2>
Per a report by Grand View Research, the global healthcare workforce management system market was valued at $1.9 billion in 2023 and is anticipated to witness a CAGR of 13.2% between 2024 and 2030. Factors like the shift toward value-based reimbursements and the increasing adoption of telehealth technologies and AI-driven analytics are likely to drive the market.
Given the market potential, the latest launch will likely provide a significant impetus to AMN Healthcare&#39;s business.
<h2>AMN Healthcare&#39;s Notable Launches</h2>
In August, AMN Healthcare launched Strategic Partnership Solutions. It aims to transform language access programs in healthcare organizations by providing comprehensive language services and strategic support to organizations.
In July, AMN Healthcare introduced a new teletherapy platform, Televate. Per the company, it has been designed to increase access to therapy services for students nationwide.
<h2>AMN&#39;s Share Price Performance</h2>
Shares of the company have lost 50.7% in the past year against the industry&#39;s 7.5% rise and the S&amp;P 500&#39;s 30.9% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/04/80821.jpg?v=2132398298" />
Image Source: Zacks Investment Research
<h2>AMN Healthcare&#39;s Zacks Rank &amp; Key Picks</h2>
Currently, AMN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Baxter International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%.
DaVita&#39;s shares have gained 74.8% compared with the industry&#39;s 31.7% rise in the past year.
Baxter, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10%. BAX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 0.7% compared with the industry&#39;s 22.9% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 62.4% compared with the industry&#39;s 22.9% rise in the past year.
<a href="https://www.zacks.com/stock/news/2347765/amn-stock-down-despite-workwise-launch-to-enhance-healthcare-delivery?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347765">To read this article on Zacks.com click here.</a>

Offerings

Small Cap

Management

Markets

Tech

Trading Ideas

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

Cardinal Health Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 11.1% in the year-to-date period against the industry&#39;s 1.7% decline. The S&amp;P 500 Index has gained 20.6% in the same time frame.&nbsp;
CAH, with a market capitalization of $27.09 billion, is a nationwide drug distributor and service provider to pharmacies, healthcare providers and manufacturers. The company has an earnings yield of 6.8% compared with the industry&#39;s 5.3%. It anticipates earnings to improve 9.6% over the next five years.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ce/80495.jpg?v=1119199146" />
Image Source: Zacks Investment Research
<h2>What&#39;s Driving CAH&#39;s Performance?</h2>
Strength in Pharmaceutical Segment:&nbsp;Investors are upbeat about Cardinal Health&#39;s Medical and Pharmaceutical offerings, which provide the company with a competitive edge in the niche space.
The segment&#39;s products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to majorly drive the quarters ahead. For the past few quarters, the segment has been acting as a key catalyst when it comes to driving growth.
In the fourth quarter of fiscal 2024, pharmaceutical revenues amounted to $55.6 billion, up 13% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
The company expects revenues from its Pharmaceutical segment to decline 4-6% year over year in fiscal 2025. The anticipated decline reflects a $39 billion revenue headwind due to the OptumRx contract expiration in June 2024. Segmental profit is likely to increase 1-3% from the previous guidance of at least 1%.
Long-term Supply Agreements:&nbsp;Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms, which have likely kept the investors interested. The company entered into a long-term strategic agreement with Henry Schein. Under this deal, Henry Schein purchased Cardinal Health&#39;s medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to CAH&#39;s earnings in the long term.
The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this should help CAH leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the United States and Canada.
Strong Q4 Results:&nbsp;Cardinal Health&#39;s impressive fourth-quarter fiscal 2024 results buoy optimism. The company&#39;s robust top-line results and solid performance in the Pharmaceutical segment were encouraging. Per management, the segmental performance was driven by brand and specialty pharmaceutical sales growth from existing customers.
Gross profit increased 5% year over year, driven by segmental growth.
<h2>Notable Developments</h2>
Last month, CAH announced an agreement to acquire Integrated Oncology Network (&quot;ION&quot;) for $1.115 billion in cash. ION will enhance CAH&#39;s oncology strategy, adding value for providers and patients. The partnership aims to equip community practices with advanced tools and technology, along with expertise from Specialty Networks&#39; PPS Analytics and SoNaR technology, enabling the company to deliver high-quality, patient-centered care close to home, ultimately improving patient outcomes and strengthening CAH&#39;s leadership in healthcare.
Cardinal Health signed a distribution agreement with Australia-based Telix to become the commercial radiopharmaceutical distributor to supply finished unit doses of Telix&#39;s PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.
In August, Cardinal Health announced the opening of a new distribution center in Greenville, SC. The distribution center is dedicated to the company&#39;s at-Home Solutions business, which is also expected to add roughly 200 jobs to the region over time. The opening of the new distribution center is likely to provide a boost to CAH&#39;s at-Home Solutions business and generate additional revenues to support the growing market for at-home solutions.
<h2>What&#39;s Weighing on the Stock?</h2>
Cardinal Health faces the risk of losing considerable business in case of loss of a major customer, which, in turn, can severely impair its future revenues. In this regard, post the establishment of a generic sourcing joint venture with CVS Caremark in 2014, Cardinal Health largely depends on the former for more than 20% of its revenues.
Collectively, five of Cardinal Health&#39;s main customers, including CVS, accounted for as much as 40% of its revenues. Meanwhile, the company&#39;s pharmaceutical distribution contracts with OptumRx ended in June 2024. These represented 17% of total revenues in fiscal 2023. The non-renewal of the contracts is likely to adversely impact CAH&#39;s sales in fiscal 2025.
In July, the FDA issued a warning for Cardinal Health&#39;s Presource kit plastic syringe makers, Jiangsu Shenli Medical Production Co. Ltd and Jiangsu China, who have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with the FDA regulations.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price</h3>
<img alt="Cardinal Health, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/e8/1728295731.png" style="height:251px; width:583px" title="" />
Cardinal Health, Inc. price | Cardinal Health, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $215.84 billion, indicating a 4.9% decline from the previous year&#39;s level.
The Zacks Consensus Estimate for adjusted earnings per share is pinned at $7.61, indicating a 1.1% increase from the year-ago reported numbers. The consensus estimate for adjusted EPS has improved 1 cent over the past 30 days.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy) at present.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.58%.
Universal Health Service has gained 17.9% compared with the&nbsp;industry&#39;s&nbsp;19.8% growth in the past six months.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics&#39; shares have risen 14.3% in the past six months compared with the&nbsp;industry&#39;s&nbsp;8% growth.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have lost 17.9% in the past six months against the&nbsp;industry&#39;s&nbsp;5.8% growth.
<a href="https://www.zacks.com/stock/news/2346905/reasons-to-retain-cardinal-health-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346905">To read this article on Zacks.com click here.</a>

Contracts

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

Stryker Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) has witnessed substantial gains in the year-to-date period. Shares of the company have rallied 18.6% compared with 13.4% growth of the&nbsp;industry. The S&amp;P 500 Composite has risen 20.1% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for investors at the moment.
Headquartered in Kalamazoo, MI, Stryker is one of the world&#39;s largest medical device companies operating in the global orthopedic market. The company has three business segments &mdash; Orthopaedics, MedSurg and Neurotechnology &amp; Spine.
Strength in Stryker&#39;s flagship Mako Total Knee Platform, which enables surgeons to do pre-operative planning and precise surgeries, looks promising. The company is also adopting several cost-cutting measures, including restructuring plans. Its prospects seem promising on the back of strong customer demand for its existing products as well as new launches. Stryker&#39;s recent acquisitions also raise optimism about the stock.&nbsp;
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/01/80132.jpg?v=2080810141" />
Image Source: Zacks Investment Research
<h2>Catalysts for Stryker&#39;s Growth</h2>
The surge in the company&#39;s share price can be attributed to its advanced robotic arm-assisted surgery platform, Mako, a strong product lineup and strategic acquisitions. The positive sentiment, driven by a solid second-quarter fiscal 2024 performance and promising business potential, is expected to continue aiding it.
Stryker ended the second quarter on a high note, with both earnings and revenues showing year-over-year improvement. The company saw robust performance in the U.S. market, particularly in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako, which likely boosted the stock&#39;s price.
SYK has increased its revenue and earnings forecasts for fiscal 2024, likely attracting investor interest. The company now anticipates organic revenue growth of 9-10% for fiscal 2024, up from the previous guidance of 8.5-9.5%. Adjusted earnings per share for 2024 are now expected to be between $11.90 and $12.10, indicating 12% growth at the midpoint compared with the earlier projection of $11.85-$12.05.
SYK&#39;s extensive product range has also garnered investor optimism. Its broad product spectrum shields it from significant sales declines during economic downturns. The company&#39;s vast experience in medical robotics, artificial intelligence and mechatronics has kept it at the forefront of the MedTech industry.
In August, SYK launched the Pangea Plating System, which received FDA clearance in late 2023. The Pangea System offers variable-angle plating for diverse patient demographics with a comprehensive and adaptable portfolio. With the Pangea System, Stryker has become a key partner for trauma-related products, including plates, nails and external fixation devices, supported by dedicated staff and excellent service.
In June, Stryker introduced the LIFEPAK 35 monitor/defibrillator, a device featuring advanced technology aimed at improving workflow efficiency and providing advanced clinical solutions for emergency responders and healthcare professionals. Additionally, the company launched the Gamma4 Hip Fracture Nailing System in Germany on June 4.
In addition to expanding organically, Stryker has bolstered its expansion by way of acquisitions. Last month, the company completed the buyout of Vertos Medical, a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.As a result of the acquisition, Stryker is set to expand its minimally invasive pain management portfolio with differentiated treatments and expand its reach across ambulatory surgery centers.
In June, Stryker also acquired care.ai, a privately held company specializing in AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The company closed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage procedures, in September.
SYK also announced the completion of the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast-conserving surgery, in August. In July, Stryker completed the previously announced acquisition of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures.
<h2>Risk Factors</h2>
As Stryker continues to acquire a large number of companies, which improves revenue opportunities, it is also likely to add to integration risks, putting gross and operating margins under pressure. Frequent acquisitions may affect the company&#39;s balance sheet in the form of a high level of goodwill and intangible assets.
A negative change in exchange rates is also a threat to SYK&#39;s core operations. The trend is likely to continue for the rest of 2024, though, at a slower pace. The company is also facing inflationary pressure, leading to lower margins.
<h2>A Look at Estimates</h2>
SYK&#39;s EPS for fiscal 2024 and 2025 is projected to increase 13.2% and 12.1% to $12.00 and $13.45 on a year-over-year basis, respectively.&nbsp; The Zacks Consensus Estimate for EPS for fiscal 2024 and 2025 has remained stable over the past 30 days.
Revenues for fiscal 2024 and 2025 are anticipated to rise 9.2% and 7.8%, respectively, to $22.37 billion and $24.12 billion on a year-over-year basis.
<div class="chart_embed">
<h3>Stryker Corporation Price</h3>
<img alt="Stryker Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/bc/1727950805.png" style="height:254px; width:527px" title="" />
Stryker Corporation price | Stryker Corporation Quote
</div>
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 47% compared with the&nbsp;industry&#39;s&nbsp;47.7% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 12.3% so far this year compared with the&nbsp;industry&#39;s&nbsp;19% rise.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have declined 6.9% so far this year against the&nbsp;industry&#39;s&nbsp;13.3% growth.
<a href="https://www.zacks.com/stock/news/2345185/stryker-stock-gains-18-6-ytd-what-s-driving-its-share-price?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2345185">To read this article on Zacks.com click here.</a>

Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?

During the last three months, 6 analysts shared their evaluations of Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.17, a high estimate of $42.00, and a low estimate of $30.00. This current average represents a 4.17% decrease from the previous average price target of $39.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1727802094_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Baxter Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baxter Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baxter Intl compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Baxter Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Baxter Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Baxter Intl analyst ratings.</a>
<h2>Delving into Baxter Intl's Background</h2>
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
<h3>Understanding the Numbers: Baxter Intl's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Baxter Intl showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.24%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Baxter Intl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.97%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Baxter Intl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Baxter Intl's debt-to-equity ratio surpasses industry norms, standing at 1.75. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Baxter Intl Stock

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and raises the price target from $38 to $40.

Citigroup Maintains Neutral on Baxter Intl, Raises Price Target to $40

Baxter: Deleveraging At A Very Steep Price

BlackRock Large Cap Focus Value Fund Q3 2024 Commentary

Bearish flow noted in Baxter (BAX) with 4,379 puts trading, or 1.8x expected. Most active are Dec-24 32.5 puts and Sep-25 27.5 puts, with total vol...

Baxter put volume heavy and directionally bearish

BlackRock Mid-Cap Value Fund Q3 2024 Commentary

BlackRock High Equity Income Fund Q3 2024 Commentary

BlackRock Impact Mortgage Fund Q3 2024 Commentary

BlackRock Basic Value V.I. Fund Q3 2024 Commentary

BlackRock Sustainable U.S. Value Equity Fund Q3 2024 Commentary

Baxter International ( ($BAX) ) has provided an announcement. Peter M. Wilver will resign from Baxter International's Board of Directors at the end...

Baxter International Announces Board Changes for 2024

This week, several&nbsp;dividend stocks&nbsp;are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching thei...

Comments

Baxter Intl

Intérêt court

Baxter Intl (NYSE:BAX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL